AR072134A1 - Composiciones de nanoparticulas de inhibidores de angiogenesis - Google Patents

Composiciones de nanoparticulas de inhibidores de angiogenesis

Info

Publication number
AR072134A1
AR072134A1 ARP090100919A ARP090100919A AR072134A1 AR 072134 A1 AR072134 A1 AR 072134A1 AR P090100919 A ARP090100919 A AR P090100919A AR P090100919 A ARP090100919 A AR P090100919A AR 072134 A1 AR072134 A1 AR 072134A1
Authority
AR
Argentina
Prior art keywords
inhibitor
thalidomide
angiostatin
alpha
laminin
Prior art date
Application number
ARP090100919A
Other languages
English (en)
Inventor
Elaine Merisko-Liversidge
H William Bosch
Greta G Cary
John Pruitt
Tuula Ryde
Rajeev Jain
Amy Walters
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of AR072134A1 publication Critical patent/AR072134A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe las composiciones de nanopart¡culas comprenden al menos un inhibidor de angiogenesis poco soluble y al menos un estabilizador de superficie. Las composiciones de nanopart¡culas tienen un tamano de part¡cula promedio de menos de aproximadamente 2000 nm. La invencion tambien describe metodos de produccion y/o uso de tales composiciones. Reivindicacion 2: La composicion de la reivindicacion 1, en donde el inhibidor de angiogenesis es seleccionado de un grupo que consiste en 2-metoxiestradiol, prinomastat, batimastat, BAY 12-9566, carboxiamidotriazol, CC-1088, dextrometorfan acetico,  cido acetico de dimetilxantenona, EMD 121974, endostatina, IM-862, Metaloproteinasa de matriz, penicilamina, PTK787/ZK 222584, RPI.4610, esqualamina, lactato de esqualamina, SU5416, talidomida (+/-)-,talidomida S, thalidomide R, TNP-470, combretastatina, paclitaxel, tamoxifen, COL-3, neovastat, BMS-275291, SU6668, alfa interferon, anticuerpo anti-VEGF, Medi-522 (Vitaxina II), CAl, celecoxib, lnterleukin-12, IM862, Amillorida, prote¡na Angiostatin®, Angiostatina K1-3, Angiostatina K1-5, Captopril, DL-Difluorometilornitina-alfa, Difluorometilornitina-alfa-DL HCI, prote¡na His-Tag® EndostatinTM, Fumagillin, Herbimicina A, 4-Hidroxifenilretinamida, interferon gamma, Juglona, Laminina, Hexapeptido de Laminina, Pentapeptido de Laminina, Lavendustina A, Medroxiprogesterona, acetato de Medroxiprogesterone, Minociclina, Minociclina HCI, Inhibidor de Ribunoclease Placental, Suramina, Salt de duramina sodica, Trombospondin de plaquetas humanas, inhibidor del tejido de Metaloproteinasa 1, inhibidor del tejido del granulocito heterofilo de Metaloproteinasa 1 e inhibidor del tejido sinovial reumatoide de la Metaloproteinasa 2. Reivindicacion 12: La composicion de la reivindicacion 1, donde el estabilizador de superficie es seleccionado de un grupo que consiste en un estabilizador de superficie anionica, un estabilizador de superficie cationico, un estabilizador de superficie y lo ionico y un estabilizar de superficie zwitterioinico.
ARP090100919A 2008-03-14 2009-03-13 Composiciones de nanoparticulas de inhibidores de angiogenesis AR072134A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/076,247 US20080220075A1 (en) 2002-03-20 2008-03-14 Nanoparticulate compositions of angiogenesis inhibitors

Publications (1)

Publication Number Publication Date
AR072134A1 true AR072134A1 (es) 2010-08-11

Family

ID=40743686

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100919A AR072134A1 (es) 2008-03-14 2009-03-13 Composiciones de nanoparticulas de inhibidores de angiogenesis

Country Status (11)

Country Link
US (1) US20080220075A1 (es)
JP (1) JP2011514360A (es)
KR (1) KR20100126445A (es)
AR (1) AR072134A1 (es)
AU (1) AU2009223108A1 (es)
CA (1) CA2718189A1 (es)
IL (1) IL207893A0 (es)
MX (1) MX2010009866A (es)
NZ (1) NZ587658A (es)
TW (1) TW200942272A (es)
WO (1) WO2009114695A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9206233B2 (en) 2007-10-19 2015-12-08 University of Pittsburgh—of the Commonwealth System of Higher Education Templates for controlling synthesis of nanoparticles into discrete assemblies
KR101873499B1 (ko) 2015-02-10 2018-07-03 주식회사 원메디칼 혈관 질환 진단용 바이오 마커 및 이의 용도
WO2016135753A1 (en) * 2015-02-25 2016-09-01 Sun Pharma Advanced Research Company Ltd. Method of preparing nanoparticulate topical composition
EP3261619A4 (en) 2015-02-25 2018-10-24 Sun Pharma Advanced Research Company Ltd Nanoparticulate composition
EP3275448A4 (en) * 2015-03-24 2019-05-01 Kyowa Hakko Kirin Co., Ltd. LIPID NANOPARTICLES CONTAINING NUCLEIC ACIDS
CN114588270A (zh) 2015-09-16 2022-06-07 Dfb索里亚有限责任公司 包含紫杉烷类纳米颗粒的组合物及其用途
HUP1500618A2 (en) 2015-12-16 2017-06-28 Druggability Tech Ip Holdco Ltd Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
KR102340311B1 (ko) 2016-09-13 2021-12-20 쿄와 기린 가부시키가이샤 의약 조성물
WO2018170196A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
EP3765035A4 (en) 2018-03-16 2021-10-27 DFB Soria, LLC TOPICAL THERAPY FOR TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND ETERNAL CANCER USING TAXANNANO PARTICLES
EP3928772A1 (en) 2020-06-26 2021-12-29 Algiax Pharmaceuticals GmbH Nanoparticulate composition
KR102369827B1 (ko) * 2020-09-04 2022-03-04 (주)피알지에스앤텍 프로게리닌을 포함하는 나노현탁액 및 이의 제조방법
WO2023106447A1 (ko) * 2021-12-08 2023-06-15 (주)피알지에스앤텍 프로게리닌을 포함하는 나노현탁액 및 이의 제조방법

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2681750A (en) * 1950-12-11 1954-06-22 Jack J Booth Counter sirup dispenser and valve
US3959457A (en) * 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
JPS4932056B1 (es) * 1970-12-22 1974-08-27
US4073943A (en) * 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4001200A (en) * 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
US4917816A (en) * 1984-01-03 1990-04-17 Abco Industries, Inc. Stabilized peroxide compositions and process for producing same
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4598064A (en) * 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4639364A (en) * 1984-11-14 1987-01-27 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
US4584130A (en) * 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
WO1995024221A1 (en) * 1986-08-18 1995-09-14 The Dow Chemical Company Bioactive and/or targeted dendrimer conjugates
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
US5006650A (en) * 1987-02-11 1991-04-09 The Upjohn Company Novel N-1 substituted beta-lactams as antibiotics
US5723147A (en) * 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
KR890700586A (ko) * 1987-02-27 1989-04-25 로버어트 에이 아마테이지 피리돈 카르복실산 또는 산유도체를 함유하는 항균제 베타-락탐
US5015737A (en) * 1987-07-22 1991-05-14 The Upjohn Company Therapeutically useful beta-lactams
US4929446A (en) * 1988-04-19 1990-05-29 American Cyanamid Company Unit dosage form
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
GB8914060D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
SE464743B (sv) * 1989-06-21 1991-06-10 Ytkemiska Inst Foerfarande foer framstaellning av laekemedelspartiklar
US5116599A (en) * 1989-07-31 1992-05-26 Johns Hopkins Univ. Perfluoro-t-butyl-containing compounds for use in fluorine-19 nmr and/or mri
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
JP2687245B2 (ja) * 1989-09-29 1997-12-08 富士写真フイルム株式会社 磁気記録媒体の製造方法
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5110606A (en) * 1990-11-13 1992-05-05 Affinity Biotech, Inc. Non-aqueous microemulsions for drug delivery
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
EP0593627A1 (en) * 1991-07-05 1994-04-27 The University Of Rochester Ultrasmall non-aggregated porous particles entrapping gas-bubbles
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
ATE264671T1 (de) * 1993-02-22 2004-05-15 American Bioscience Inc Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5766627A (en) * 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5731334A (en) * 1994-01-11 1998-03-24 The Scripps Research Institute Method for treating cancer using taxoid onium salt prodrugs
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US5731356A (en) * 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5525328A (en) * 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5521168A (en) * 1994-10-13 1996-05-28 Alcon Laboratories, Inc. Estrogen metabolites for lowering intraocular pressure
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5593657A (en) * 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5500204A (en) * 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5521218A (en) * 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
GB9515214D0 (en) * 1995-07-25 1995-09-20 Univ Strathclyde Plant extracts
JP4163254B2 (ja) * 1996-01-03 2008-10-08 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ムチリンのカルバモイルオキシ誘導体および抗細菌剤としてのそれらの使用
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
CZ299790B6 (cs) * 1996-08-22 2008-11-26 Skyepharma Canada Inc. Kompozice mikrocástic ve vode nerozpustné látky, farmaceutická kompozice, zpusob prípravy stabilních cástic, mikrocástice ve vode nerozpustné nebo slabe rozpustné slouceniny, kompozice obsahující tyto mikrocástice a zpusob prípravy mikrocástic
IN186315B (es) * 1996-12-12 2001-08-04 Panacea Biotec Ltd
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US20020002294A1 (en) * 1997-09-24 2002-01-03 D' Amato Robert J. Estrogenic compounds as antiangiogenic agents
AU753540B2 (en) * 1998-03-05 2002-10-24 Agouron Pharmaceuticals, Inc. Non-peptide GnRH agents
US6228985B1 (en) * 1998-05-21 2001-05-08 Schering Corporation Derivatives of aminobenzoic and aminobiphenylcarboxylic acids useful as anti-cancer agents
IL140276A0 (en) * 1998-06-19 2002-02-10 Rtp Pharma Inc Processes to generate submicron particles of water-insoluble compounds
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6028108A (en) * 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6225311B1 (en) * 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB9913536D0 (en) * 1999-06-10 1999-08-11 Sterix Ltd Use
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
US6362234B1 (en) * 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane
US6399087B1 (en) * 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
EP1800666A1 (en) * 2002-03-20 2007-06-27 Elan Pharma International Limited Nanoparticulate compositions of angiogenesis inhibitors
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors

Also Published As

Publication number Publication date
IL207893A0 (en) 2010-12-30
CA2718189A1 (en) 2009-09-17
JP2011514360A (ja) 2011-05-06
US20080220075A1 (en) 2008-09-11
WO2009114695A1 (en) 2009-09-17
NZ587658A (en) 2012-02-24
AU2009223108A1 (en) 2009-09-17
KR20100126445A (ko) 2010-12-01
MX2010009866A (es) 2010-09-30
TW200942272A (en) 2009-10-16

Similar Documents

Publication Publication Date Title
AR072134A1 (es) Composiciones de nanoparticulas de inhibidores de angiogenesis
Vidal et al. Galloyl moieties enhance the dentin biomodification potential of plant-derived catechins
BRPI0913109B8 (pt) solução aquosa oftálmica
BRPI0606606A2 (pt) composições estáveis contendo prostaglandina
BRPI0612072A2 (pt) inibidores da aspartil protease
BRPI0607308A2 (pt) compostos, composições farmacêuticas e usos dos referidos compostos
TW201129562A (en) Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
PE20070210A1 (es) Compuestos macrociclicos como inhibidores del virus de hepatitis c
BR0314611A (pt) Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
NO20064355L (no) Nye ketoamider med sykliske P4-er som inhibitorer for NS3-serinprotease fra hepatitt C-virus
WO2011156672A4 (en) Compositions for treating skin
BRPI1011804A2 (pt) composição farmacêutica com solubilidade melhorada
CO2019012164A2 (es) Métodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3
AR120683A1 (es) Compuestos de benzoti(di)azepina y su uso como ácido biliar
BR112012015188A8 (pt) composição e método para o tratamento e/ou a prevenção de uma doença ocular relacionada à angiogênese
TW200716184A (en) Inhibitor for parakeratosis, pore reducing agent or skin roughening preventing or ameliorating agent and composition for skin care preparation
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
AR040928A1 (es) Compuestos de acidos sulfona-hidroxamicos aromaticos, composiciones farmaceuticas y su uso en la preparacion de medicamentos utiles como inhibidores de proteasas
AR099201A1 (es) Composiciones de limpieza que contienen plata estable
BR112022001365A2 (pt) Formas cristalinas de um inibidor de cd73
BR112022012986A2 (pt) Soluções orais compreendendo sais de lisdexamfetamina
BRPI1007471A8 (pt) Composições de enxágue para cuidados pessoais
AR040895A1 (es) Composiciones liquidas multifase par a limpieza y/o desinfeccion de superficies duras
ATE540026T1 (de) Hydroxyphenylsulfonsäureamide als antiapoptotische bcl-inhibitoren

Legal Events

Date Code Title Description
FB Suspension of granting procedure